Celularity

Celularity EPS Growth

The EPS Growth of Celularity (CELU) as of Oct 16, 2026 is -23.98 %. In the previous year, EPS Growth was 75.37 % — a change of -131.82% (lower).

EPS Growth

-23.98 %

YoY

-131.82%

Last updated:

EPS Growth of Celularity is 2025 -23.98 % . EPS Growth of Celularity was 2024 75.37 % . It decreases by -131.82% lower compared to the previous year.

The Celularity EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2019
-8.06 M USD
Jan 1, 2020
-27.69 USD
Jan 1, 2021
92.86 USD
Jan 1, 2022
111.81 USD
Jan 1, 2023
-1,193.79 USD
Jan 1, 2024
75.37 USD
Jan 1, 2025
-23.98 USD
The Celularity EPS Growth history
YEAREPS GrowthYoY
-23.98 %-131.82%
75.37 %-106.31%
-1,193.79 %-1,167.64%
111.81 %+20.41%
92.86 %-435.32%
-27.69 %-100.00%
-8.06 M %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celularity Stock analysis

What does Celularity do? Celularity Inc, listed on the stock market with ticker CELU and ISIN US1511902041, is a biotechnology company headquartered in Florham Park, New Jersey, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Celularity has 225 employees and completed its initial public offering (IPO) on May 23, 2019. The company focuses on developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune disorders, and infectious diseases. Its research and development efforts include various therapy product candidates such as T cells engineered with a chimeric antigen receptor (CAR), natural killer cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target a range of conditions including cancer, infectious diseases, and degenerative diseases. Celularity's product pipeline features several programs, including CYCART-19, which is a placental-derived CAR-T cell therapy targeting B-cell malignancies, and pEXO-001, among others. The company's operations are structured around three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Celularity's website is https://celularity.com/. Celularity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celularity stock

EPS Growth of Celularity is -23.98 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth Celularity since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Celularity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Celularity

All Key Metrics — Celularity